

January 23, 2009

Co-Promotion Agreement of "FOSAMAC[®]"

Banyu Pharmaceutical Co., Ltd., (Chiyoda-ku, Tokyo, Representative: Mark Timney "Banyu") and Hisamitsu Pharmaceutical Co., Inc., (Tosu-shi, Saga, President & Chief Executive Officer: NAKATOMI, Hirotaka "Hisamitsu") today announced that the companies have signed a Co-Promotion Agreement of FOSAMAC[®] (alendronate sodium).

Under this agreement, the both companies will begin co-promotion of the pharmaceutical ethical products "FOSAMAC[®] tablets-5" and "FOSAMAC[®] tablets 35mg" to physicians from March 2009. "Banyu" retains the rights for sole responsibility to manufacture, distribute and sell the product.

Banyu intends to further strengthen its position in osteoporosis market by bringing greater reach to our customers. Hisamitsu is an innovative pharmaceutical company dedicated to orthopedic area and has already established strong relationships with customers in this area.

Both parties expect to maximize its efforts to support customers' needs for medical information and increased understanding of the appropriate use of FOSAMAC[®] through this co-promotion agreement. By doing this, both parties can help further improve patient care.